coyatherapeutics.com
  • About Us
      • Back
      • Story and Approach
      • Management Team
  • Science & Technology
      • Back
      • Treg Overview
      • Manufacturing Overview
      • Exosome Overview
      • Publications
  • Pipeline
      • Back
      • Pipeline
      • Indications
  • News
      • Back
      • News
      • Press Releases
      • Blog
      • Presentations
      • Events
  • Patient Resources
      • Back
      • Clinical Trial Information
  • Contact Us
line

Coya Raises $10M to Advance T-cell Therapy Now in Phase 2 ALS Trial

  • Science News
View full article: 
https://hcp.alsnewstoday.com/2021/02/05/coya-raises-10m-to-advance-t-cell-therapy-now-in-phase-2-als-trial/

Disclaimer:
These links are being provided as a convenience and for informational purposes only; they do not constitute an endorsement or an approval by Coya Therapeutics of any of the products, services or opinions of the corporation or organization or individual. Coya Therapeutics bears no responsibility for the accuracy, legality or content of the external site or for that of subsequent links. Contact the external site for answers to questions regarding its content.

Harnessing adoptive
regulatory T cells (Tregs)
to target disease

Contact Us
Gantry 5
© 2022 Coya Therapeutics, Inc. All rights reserved
  • About Us
      • Back
      • Story and Approach
      • Management Team
  • Science & Technology
      • Back
      • Treg Overview
      • Manufacturing Overview
      • Exosome Overview
      • Publications
  • Pipeline
      • Back
      • Pipeline
      • Indications
  • News
      • Back
      • News
      • Press Releases
      • Blog
      • Presentations
      • Events
  • Patient Resources
      • Back
      • Clinical Trial Information
  • Contact Us
Terms of Use  Privacy Policy  

Follow Us

5850 San Felipe St Suite 500
Houston TX 77057
1 (800) 587-8170

Harnessing potent
immunomodulatory T cells (Tregs) and TREG derived
Exosomes to target disease

Contact Us